Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.

@article{Broniscer2010PhaseIS,
  title={Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.},
  author={Alberto Broniscer and Justin Nathaniel Baker and Michael Tagen and Francesco Travascio and Richard J. Gilbertson and Andrew M. Davidoff and Atmaram S. Pai Panandiker and Wing Wah Leung and Thomas K. Chin and Clinton F Stewart and Mehmet Koçak and Christopher G. Rowland and Thomas E. Merchant and Sue Creviston Kaste and Amar Gajjar},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 31},
  pages={
          4762-8
        }
}
PURPOSE To evaluate the safety, maximum-tolerated dose, pharmacokinetics, and pharmacodynamics of vandetanib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor inhibitor, administered once daily during and after radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. PATIENTS AND METHODS Radiotherapy was administered as 1.8-Gy fractions (total cumulative dose of 54 Gy). Vandetanib was administered concurrently with… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 50 CITATIONS, ESTIMATED 52% COVERAGE

Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2013
VIEW 6 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Diffuse intrinsic pontine glioma: poised for progress

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

  • Cold Spring Harbor perspectives in medicine
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Severe photosensitivity reaction to vandetanib.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 1 EXCERPT